SOPHiA GENETICS Unveils New Tool to Monitor Acute Myeloid Leukemia
SOPHiA GENETICS Unveils New Tool to Monitor Acute Myeloid Leukemia
SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.
SOPHiA GENETICS（纳斯达克：SOPH）是一家云原生医疗科技公司和全球数据驱动医学领域的领导者，今天宣布推出新的残留急性髓细胞白血病（RAM）应用程序。这一新业务扩展了公司全面的肿瘤学产品线，支持可衡量残留病情的能力，并将于今年夏天在全球范围内向客户提供。
Acute Myeloid Leukemia (AML) represents about one percent of all cancers worldwide, yet is one of the most common forms of leukemia in adults1. Over 50 percent of AML patients relapse within 3 years after achieving complete remission2, therefore post-treatment monitoring is imperative for AML patients, particularly within the first two years, to help quickly detect any signs of relapse3. MRD solutions can help inform post-remission therapy and identify early relapse, and serve as a primary endpoint in clinical trials, helping researchers detect even the smallest trace of cancer and support better patient outcomes.
急性髓细胞白血病（AML）占全球所有癌症的约1％，但是是成人白血病的最常见形式之一。2在完全缓解后3年内，超过50％的AML患者会复发。因此，AML患者的治疗后监测至关重要，特别是在前两年内，以帮助快速检测出任何复发迹象。MRD解决方案可以帮助了解缓解后治疗情况并确定早期复发，并作为临床试验的主要终点，帮助研究人员检测到甚至是最小的癌症痕迹，支持更好的患者预后。